Cingulate Inc. (NASDAQ:CING) announced the successful completion of its final FDA-required study for CTx-1301 (dexmethylphenidate) aimed at treating Attention Deficit Hyperactivity Disorder (ADHD).
With today’s fast life, most men find it very challenging to stay updated with perfect health and virility. Physical, mental, and sexual performances suffer most because of stress, life habits, and ...